Larger multicenter-studies would be necessary to better understand the responsiveness to TKIs of NSCLC with EGFR/ALK co-alterations, as the available data, despite constantly growing, are based on few and inconsistent case reports that do not allow to draw definitive conclusions. The gene discussed is ALK; the disease is non-small cell lung carcinoma.